Breast cancer: Hologic touts 'excellent' results from 7-year MammoSite registry
Women's health company Hologic releases final results from the 7-year MammoSite registry of breast cancer patients treated with breast brachytherapy.
Massachusetts women's health company Hologic (NSDQ:HOLX) rang in Breast Cancer Awareness Month with the release of registry data from the MammoSite trial, a 7-year study of more than 1,400 patients treated with breast brachytherapy.
MammoSite therapy is a breast-conserving treatment that delivers targeted radiation to areas deemed most likely for the re-emergence of cancerous growth. The final analysis of patients in Hologic's registry found low rates of local recurrent, greater than 90% long-term cosmesis (retention of aesthetic appearance) and less than 10% toxicity, according to a company statement.